131 related articles for article (PubMed ID: 26199214)
21. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
22. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
23. Molecular Landscape and Computational Screening of the Natural inhibitors against HPV16 E6 Oncoprotein.
Juneja T; Pandya MD; Shah S
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2461-2469. PubMed ID: 34452559
[TBL] [Abstract][Full Text] [Related]
24. Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cells.
Yuan CH; Filippova M; Krstenansky JL; Duerksen-Hughes PJ
Cell Death Dis; 2016 Jan; 7(1):2060. PubMed ID: 26794656
[TBL] [Abstract][Full Text] [Related]
25. Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.
Bonetta AC; Mailly L; Robinet E; Travé G; Masson M; Deryckere F
Biochem Biophys Res Commun; 2015 Oct; 465(4):658-64. PubMed ID: 26241675
[TBL] [Abstract][Full Text] [Related]
26. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
27. In Silico Docking to Explicate Interface between Plant-Originated Inhibitors and E6 Oncogenic Protein of Highly Threatening Human Papillomavirus 18.
Kumar S; Jena L; Sahoo M; Kakde M; Daf S; Varma AK
Genomics Inform; 2015 Jun; 13(2):60-7. PubMed ID: 26175664
[TBL] [Abstract][Full Text] [Related]
28. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
29. Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients.
Chen SP; Hsu NY; Wu JY; Chen CY; Chou MC; Lee H; Cheng YW
Ann Thorac Surg; 2013 Apr; 95(4):1196-203. PubMed ID: 23522190
[TBL] [Abstract][Full Text] [Related]
30. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
Bourguignon LYW; Earle C; Shiina M
Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
[TBL] [Abstract][Full Text] [Related]
32. Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis.
Braun JA; Herrmann AL; Blase JI; Frensemeier K; Bulkescher J; Scheffner M; Galy B; Hoppe-Seyler K; Hoppe-Seyler F
Int J Cancer; 2020 Jan; 146(2):461-474. PubMed ID: 31603527
[TBL] [Abstract][Full Text] [Related]
33. A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells.
Messa L; Celegato M; Bertagnin C; Mercorelli B; Nannetti G; Palù G; Loregian A
Sci Rep; 2018 Apr; 8(1):6020. PubMed ID: 29662081
[TBL] [Abstract][Full Text] [Related]
34. Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues.
Malik RM; Fazal S; Kamal MA
Protein Pept Lett; 2021; 28(4):414-425. PubMed ID: 32703126
[TBL] [Abstract][Full Text] [Related]
35. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
36. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
37. Solution structure of the hDlg/SAP97 PDZ2 domain and its mechanism of interaction with HPV-18 papillomavirus E6 protein.
Liu Y; Henry GD; Hegde RS; Baleja JD
Biochemistry; 2007 Sep; 46(38):10864-74. PubMed ID: 17713926
[TBL] [Abstract][Full Text] [Related]
38. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.
He L; Zhang E; Shi J; Li X; Zhou K; Zhang Q; Le AD; Tang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):713-25. PubMed ID: 23292117
[TBL] [Abstract][Full Text] [Related]
39. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7.
Maher DM; Bell MC; O'Donnell EA; Gupta BK; Jaggi M; Chauhan SC
Mol Carcinog; 2011 Jan; 50(1):47-57. PubMed ID: 21061268
[TBL] [Abstract][Full Text] [Related]
40. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
Front Immunol; 2018; 9():3000. PubMed ID: 30619353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]